WO1999063116A3 - Use of prothymosin in the diagnosis and treatment of endometriosis - Google Patents
Use of prothymosin in the diagnosis and treatment of endometriosis Download PDFInfo
- Publication number
- WO1999063116A3 WO1999063116A3 PCT/US1999/012336 US9912336W WO9963116A3 WO 1999063116 A3 WO1999063116 A3 WO 1999063116A3 US 9912336 W US9912336 W US 9912336W WO 9963116 A3 WO9963116 A3 WO 9963116A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prothymosin
- endometriosis
- diagnosis
- treatment
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU42305/99A AU760613B2 (en) | 1998-06-04 | 1999-06-03 | Use of prothymosin in the diagnosis and treatment of endometriosis |
US09/485,193 US6753138B1 (en) | 1998-06-04 | 1999-06-03 | Use of prothymosin in the diagnosis and treatment of endometriosis |
CA002299436A CA2299436A1 (en) | 1998-06-04 | 1999-06-03 | Use of prothymosin in the diagnosis and treatment of endometriosis |
JP2000552308A JP2002517209A (en) | 1998-06-04 | 1999-06-03 | Use of prothymosin in diagnosis and treatment of endometriosis |
EP99926150A EP1002136A2 (en) | 1998-06-04 | 1999-06-03 | Use of prothymosin in the diagnosis and treatment of endometriosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8801698P | 1998-06-04 | 1998-06-04 | |
US60/088,016 | 1998-06-04 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/485,193 A-371-Of-International US6753138B1 (en) | 1998-06-04 | 1999-06-03 | Use of prothymosin in the diagnosis and treatment of endometriosis |
US10/654,592 Division US20040096884A1 (en) | 1998-06-04 | 2003-09-02 | Use of prothymosin in the diagnosis and treatment of endometriosis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999063116A2 WO1999063116A2 (en) | 1999-12-09 |
WO1999063116A3 true WO1999063116A3 (en) | 2000-03-02 |
Family
ID=22208698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/012336 WO1999063116A2 (en) | 1998-06-04 | 1999-06-03 | Use of prothymosin in the diagnosis and treatment of endometriosis |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1002136A2 (en) |
JP (1) | JP2002517209A (en) |
AU (1) | AU760613B2 (en) |
CA (1) | CA2299436A1 (en) |
WO (1) | WO1999063116A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001023572A2 (en) * | 1999-09-30 | 2001-04-05 | Curagen Corporation | Polynucleotides and polypeptides encoded thereby |
EP1801236B1 (en) * | 2000-02-25 | 2009-11-18 | Siemens Healthcare Diagnostics Inc. | Endometriosis related markers and uses thereof |
US6777182B2 (en) * | 2000-02-25 | 2004-08-17 | Metriogene Biosciences Inc. | Methods for determining the likelihood of endometriosis in a female subject |
EP1321768A1 (en) * | 2001-12-18 | 2003-06-25 | Roche Diagnostics GmbH | Diagnosis of endometriosis from menstrual blood |
CA2489568A1 (en) * | 2002-05-14 | 2004-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Endometrial genes in endometrial disorders |
US7268117B2 (en) | 2003-07-11 | 2007-09-11 | Praecis Pharmaceuticals Incorporated | Compositions, kits, and methods for identification, assessment, prevention, and therapy of endometriosis |
AU2004303448A1 (en) * | 2003-12-23 | 2005-07-07 | Mount Sinai Hospital | Methods for detecting markers associated with endometrial disease or phase |
US20060008876A1 (en) | 2004-07-07 | 2006-01-12 | Shami A S E | ME-5, ME-2, and EPP2: human protein antigens reactive with autoantibodies present in the serum of women suffering from endometriosis |
EP1931993A2 (en) * | 2005-09-14 | 2008-06-18 | Medizinische Universität Wien | Means and methods for diagnosing endometriosis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4696915A (en) * | 1984-05-25 | 1987-09-29 | Hoffmann-La Roche Inc. | Parathymosin alpha |
US5248591A (en) * | 1991-05-02 | 1993-09-28 | Puente Fernando D | Diagnosis of cancer and other proliferative disorders by analysis of prothymosin alpha expression |
WO1995032708A1 (en) * | 1994-05-26 | 1995-12-07 | Metris Therapeutics Limited | Use of anti-vegf agents in the treatment of endometriosis |
WO1998012324A1 (en) * | 1996-09-18 | 1998-03-26 | Center For Blood Research, Inc. | Monocyte chemotactic protein 5 (mcp-5) molecules and uses therefor |
WO1998042185A1 (en) * | 1997-03-26 | 1998-10-01 | Reprogen, Inc. | Endometriosis mouse model |
-
1999
- 1999-06-03 WO PCT/US1999/012336 patent/WO1999063116A2/en not_active Application Discontinuation
- 1999-06-03 AU AU42305/99A patent/AU760613B2/en not_active Ceased
- 1999-06-03 CA CA002299436A patent/CA2299436A1/en not_active Abandoned
- 1999-06-03 JP JP2000552308A patent/JP2002517209A/en not_active Withdrawn
- 1999-06-03 EP EP99926150A patent/EP1002136A2/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4696915A (en) * | 1984-05-25 | 1987-09-29 | Hoffmann-La Roche Inc. | Parathymosin alpha |
US5248591A (en) * | 1991-05-02 | 1993-09-28 | Puente Fernando D | Diagnosis of cancer and other proliferative disorders by analysis of prothymosin alpha expression |
WO1995032708A1 (en) * | 1994-05-26 | 1995-12-07 | Metris Therapeutics Limited | Use of anti-vegf agents in the treatment of endometriosis |
WO1998012324A1 (en) * | 1996-09-18 | 1998-03-26 | Center For Blood Research, Inc. | Monocyte chemotactic protein 5 (mcp-5) molecules and uses therefor |
WO1998042185A1 (en) * | 1997-03-26 | 1998-10-01 | Reprogen, Inc. | Endometriosis mouse model |
Non-Patent Citations (6)
Title |
---|
BAXEVANIS ET AL.: "PROTHYMOSIN ALPHA ENHANCES HUMAN AND MURINE MHC CLASS II SURFACE ANTIGEN EXPRESSION AND MESSENGER RNA ACCUMULATION", J.IMMUNOL., vol. 148, no. 7, 1992, pages 1979 - 1984, XP002125674 * |
DATABASE MEDLINE July 1998 (1998-07-01), OTA ET AL.: "IS ADENOMYOSIS AN IMMUNE DISEASE", XP002123261 * |
HILL: "IMMUNOLOGY AND ENDOMETRIOSIS", OBSTET GYNECOL CLIN NORTH AM, vol. 24, no. 2, 1997, pages 291 - 306, XP000857031 * |
OIKAWA ET AL.: "EXPRESSION OF GONADOTROPIN-RELEASING HORMONE AND PROTHYMOSIN-ALPHA MESSENGER RIBONUCLEIC ACID IN THE OVARY", ENDOCRINOLOGY, vol. 127, no. 5, 1990, XP000857700 * |
OTA AND IGARASHI: "EXPRESSION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II ANTIGEN IN ENDOMETRIC TISSUE IN PATIENTS WITH ENDOMETRIOSIS AND ADENOMYOSIS", FERTIL STERIL, vol. 60, no. 5, 1993, pages 834 - 838, XP000857027 * |
SHARPE-TIMMS: "BASIC RESEARCH IN ENDOMETRIOIS", OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, vol. 24, no. 2, June 1997 (1997-06-01), pages 269 - 290, XP000853792 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999063116A2 (en) | 1999-12-09 |
CA2299436A1 (en) | 1999-12-09 |
JP2002517209A (en) | 2002-06-18 |
EP1002136A2 (en) | 2000-05-24 |
AU760613B2 (en) | 2003-05-22 |
AU4230599A (en) | 1999-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999063115A3 (en) | Use of cathepsin s in the diagnosis and treatment of endometriosis | |
WO2003069332A3 (en) | Detection and/or monitoring of synuclein-related diseases | |
WO2002018652A3 (en) | Method for detection of htr and htert telomerase-associated rna in plasma or serum | |
NO973381L (en) | Diagnostic test device with test layers consisting of several layers, and method for determining an analyte by means of this | |
WO1994015268A3 (en) | Method and device for signal analysis, process identification and monitoring of a technical process | |
AU2002327308A1 (en) | Methods for evaluating pathologic conditions using extracellular rna | |
EP1757937A3 (en) | Use of HMG1 in the diagnosis of inflammatory conditions | |
CA2346055A1 (en) | Method and device for predicting physiological values | |
EP1645227A3 (en) | Device and method for segmental bioimpedance measurements of a dialysis patient | |
CA2332112A1 (en) | Monitoring of physiological analytes | |
EP1141699A4 (en) | Devices and methods for performing blood coagulation assays by piezoelectric sensing | |
EP1260815A3 (en) | Methods for automatically monitoring analyte concentration using minimally invasive devices | |
WO2005028675A3 (en) | Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc) | |
ES2133813T3 (en) | LAMININE CHAINS: DIAGNOSIS AND THERAPEUTIC USE. | |
WO1999063116A3 (en) | Use of prothymosin in the diagnosis and treatment of endometriosis | |
WO1999016351A8 (en) | Methods and apparatus for r-wave detection | |
WO2004043223A3 (en) | Compositions and methods for the diagnosis and treatment of sepsis | |
WO2004031414A3 (en) | Method for diagnosing prostate cancer | |
EP2327451A3 (en) | Method for detecting and inhibiting angiogenesis | |
CA2283996A1 (en) | Estimating permeability | |
WO1995024650A3 (en) | Methods of diagnosing and treating preeclampsia | |
WO2002095358A3 (en) | System and method for monitoring or treating a health condition | |
WO2004071273A3 (en) | Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus | |
WO2002059611A3 (en) | Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides | |
WO1999061072A3 (en) | Methods of inhibiting clot formation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2299436 Country of ref document: CA Ref country code: CA Ref document number: 2299436 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 552308 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 42305/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999926150 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 1999926150 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09485193 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 42305/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999926150 Country of ref document: EP |